There’s No Getting Around Amarin Corp ADR (NASDAQ: AMRN) Success

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Amarin Chairman & CEO Issue Letter to Shareholders.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

AMRN belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – General industry. At the end of the last regular session, the stock closed at $1.23 and fluctuated between $1.2400 as its day high and $1.1700 as its day low. The current market capitalization of Amarin Corp ADR is $502.52M. A total of 0.97 million shares were traded on the day, compared to an average of 2.35M shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, AMRN has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 4 BUYs and 6 SELLs from insiders. Insiders purchased 124,267 shares during that period but sold 97,253.

In the most recent transaction, Holt Patrick bought 14,426 shares of AMRN for 1.09 per share on Jan 22. After the transaction, the President and CEO now owns 314,426 company shares. In a previous transaction on Dec 12, Ketchum Steven B sold 34,131 shares at 0.79 per share. AMRN shares that Chief Scientific Officer owns now total 566,100.

Among the insiders who bought shares, Holt Patrick acquired of 300,000 shares on Aug 16 at a per-share price of $1.04. This resulted in the President and CEO holding 300,000 shares of AMRN after the transaction.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for AMRN in the last 3 months, the mean price target is $1.42 with high estimates of $2.00 and low estimates of $1.00. In terms of 52-week highs and lows, AMRN has a high of $2.23 and a low of $0.65.

As of this writing, AMRN has an earnings estimate of -$0.03 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.03 per share and a lower estimate of -$0.05. The company reported an EPS of -$0.04 in the last quarter, which was -33.30% lower than expectations of -$0.03.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. AMRN’s latest balance sheet shows that the firm has $454.13M in Cash & Short Term Investments as of fiscal 2021. There were $8.58M in debt and $370.68M in liabilities at the time. Its Book Value Per Share was $1.35, while its Total Shareholder’s Equity was $667.10M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AMRN is Buy with a score of 2.60.

Most Popular

Related Posts